Item 8.01 Other Events

On April 8, 2022, Seagen Inc. ("Seagen") issued a press release announcing that a jury in the U.S. District Court for the Eastern District of Texas found that Daiichi Sankyo Co. Ltd. infringed Seagen's U.S. Patent No. 10,808,039 by selling in the United States its ENHERTU® product (trastuzumab deruxtecan; DS-8201). The press release is attached as Exhibit 99.1 to this current report and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits



99.1     Press Release of Seagen Inc. dated April 8, 2022

104    Cover Page Interactive Data File (formatted in Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses